ITGAM and lymphoma: As expected the mean percentage of each subpopulation was significantly higher in the whole series of lymphoma patients as compared to healthy donors: CD11b+CD16+ (4.59 ± 0.99 vs 0.28 ± 0.04, p < 0.0001), CD11b+CD16− (1.21 ± 0.25 vs 0.16 ± 0.03, p < 0.001), and CD11b−CD16− (0.47 ± 0.13 vs 0.08 ± 0.01, p = 0.004) (Figure 3A).